# Glycidol

| CAS number: | 556-52-5 |
| --- | --- |
| Synonyms: | 2,3-Epoxy-1-propanol, epoxypropyl alcohol, glycide, Oxiranemethanol |
| Chemical formula: | C3H6O2 |

 Workplace exposure standard (interim)

| TWA: | **2 ppm (6.1 mg/m3)** |
| --- | --- |
| STEL: | **—** |
| Peak limitation: | **—** |
|  Notations: | **Carc. 1B, Sk.** |
| IDLH: | **150 ppm** |
| **Sampling and analysis:** The recommended value is likely to be below the current limit of detection for standard sampling and analysis techniques. |

## Recommendation and basis for workplace exposure standard

A TWA of 2 ppm (6.1 mg/m3) is recommended to minimise the potential for cancer in exposed workers.

Given the limited data available from the primary sources, it is recommended that a review of additional sources be conducted at the next scheduled review.

## Discussion and conclusions

Glycidol is primarily used as a stabiliser in the manufacture of vinyl polymers.

Based on evidence in animals, it is considered to be an animal carcinogen with the potential to cause cancer in humans (ACGIH, 2018; DFG, 2015; NICNAS, 2015). Insufficient evidence exists to determine if carcinogenicity is manifested *via* a non-threshold genotoxic mechanism.

Toxicological data in humans are limited to one worker study that reported no adverse effects at 2 ppm (ACGIH, 2018). A TWA of 2 ppm (6.1 mg/m3) is recommended as derived by ACGIH (2018). This TWA is cited to minimise the potential risk of cancer.

## Recommendation for notations

Classified as a category 1B carcinogen according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS).

Not classified as a skin sensitiser or respiratory sensitiser according to the GHS.

A skin notation is recommended based on evidence of systemic effects in rabbits following dermal application and the potential for multi-organ cancer effects.

# Appendix

### Primary sources with reports

| Source Year set Standard  |
| --- |
| SWA 1991 TWA: 25 ppm (76 mg/m3) |
|  |
| ACGIH 2001 TLV-TWA: 2 ppm (6.1 mg/m3) |
| TLV-TWA is recommended to minimise the potential risk of cancer and genotoxicity.Summary of data:Human data:* Glycidol manufacturer report: 70 workers exposed ≤2 ppm; no adverse effects.

Animal data:* LC50: 450 ppm (mice, 4 h)
* LD50:1,980 mg/kg (rabbits, dermal)
* Irritating to rabbit skin; repeated applications caused severe irritation after 4 d
* Dose-related increase in neoplasia in rats and mice exposed by gavage dosing for 2 yr; 37.5 or 75 mg/kg/d in rats or 25 or 50 mg/kg/d in mice:
* prominent lesion in male rats include mesothelioma in the tunica vaginalis with metastasis into the peritoneal cavity; mesotheliomas occurred in 3/49 of the vehicle controls, 34/50 of the low-dose (38 mg/kg), and 39/47 of high-dose (75 mg/kg) male rats
* neoplasms of the mammary gland were prominent in female rats
* dose-related increases in the incidences of neoplasms of the mammary gland, brain, thyroid gland and forestomach in male and female rats
* harderian gland neoplasms were increased in mice of each sex
* incidences of adenomas, fibroadenomas or adenocarcinomas (combined) of the mammary gland in female mice were markedly increased; combined incidences of fibroadenomas and adenocarcinomas were 14/50 in vehicle control, 34/48 in the low-dose, and 37/48 in high-dose female rats
* forestomach, liver and lung neoplastic lesions were increased in male mice.

Genotoxicity:* Induced unscheduled DNA synthesis in human W138 cells
* Induced mutations in *S. typhimurium* both with and without S9 activation; no further information
* Positive in the absence of exogenous metabolic activation in the mouse lymphoma assay.
 |
| DFG 2015 Not assigned |
| Summary of additional data:* No MAK due to carcinogenicity
* Carcinogenic in various organs of the rat and mouse after oral administration
* Genotoxic *in vitro* and *in vivo* in almost all somatic cell tests.
 |
| SCOEL NA NA |
| No report. |
| OARS/AIHA NA NA |
| No report. |
| HCOTN NA NA |
| No report. |

### Secondary source reports relied upon

| Source |  | Year | Additional information |
| --- | --- | --- | --- |
| NICNAS |  | 2015 | * Repeated dermal exposure for 7 d caused mortalities in rabbits:
* indication of systemic toxicity effects in animals 48 h before death
* the dose administered ≈114 mg/kg/d
* 520 d dermal carcinogenicity study in mice; no tumours observed.
 |
| IARC |  | 2000 | * Direct-acting alkylating agent that is mutagenic in a wide range of *in vivo* and *in vitro* test systems.
 |
| NTP |  | 2009 | * Reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.
 |

### Carcinogenicity — non-threshold based genotoxic carcinogens

| Is the chemical mutagenic? | Yes |
| --- | --- |
| Is the chemical carcinogenic with a mutagenic mechanism of action? | Insufficient data |
| **Insufficient data are available to determine if the chemical is a non-threshold based genotoxic carcinogen.** |

## Notations

| Source | Notations  |
| --- | --- |
| SWA | Carc. 1B |
| HCIS | Carcinogenicity – category 1B |
| NICNAS | Carc. Cat 2, Skin |
| EU Annex | Carcinogenicity – category 1B |
| ECHA | Carc. 1B |
| ACGIH | Carcinogenicity – A3 |
| DFG | Carcinogenicity – 2, H (skin) |
| SCOEL | NA |
| HCOTN | NA |
| IARC | Carcinogenicity – Group 2A |
| US NIOSH | NA |

NA = not applicable (a recommendation has not been made by this Agency); — = the Agency has assessed available data for this chemical but has not recommended any notations

### Skin notation assessment

| Calculation  |
| --- |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Conclusion:** |   |   |   |   |   |
|  |   | Adverse effects in human case study: |   |   |   |
|   |   | Dermal LD50 ≤1000 mg/kg: | yes | 3.00 |   |
|   |   | Dermal repeat-dose NOAEL ≤200 mg/kg: |   |   |   |
|   |   | Dermal LD50/Inhalation LD50 <10: |   |   |   |
|   |   | *In vivo* dermal absorption rate >10%: |   |   |   |
|   |   | Estimated dermal exposure at WES >10%: |   |   |   |
|   |   |   | **consider assigning a skin notation** |

### IDLH

| Is there a suitable IDLH value available? | Yes |
| --- | --- |

## Additional information

| Molecular weight: | 74.08 |
| --- | --- |
| Conversion factors at 25°C and 101.3 kPa:  | 1 ppm = 3.03 mg/m3; 1 mg/m3 = 0.33 ppm |
| This chemical is used as a pesticide: |[ ]
| This chemical is a biological product: |[ ]
| This chemical is a by-product of a process: |[ ]
| A biological exposure index has been recommended by these agencies: | [ ]  ACGIH [ ]  DFG [ ]  SCOEL  |

## Workplace exposure standard history

| Year | Standard |
| --- | --- |
| Click here to enter year |  |

## References

American Conference of Industrial Hygienists (ACGIH®) (2018) TLVs® and BEIs® with 7th Edition Documentation, CD-ROM, Single User Version. Copyright 2018. Reprinted with permission. See the [*TLVs® and BEIs® Guidelines section*](http://www.acgih.org/tlv-bei-guidelines/policies-procedures-presentations) on the ACGIH website.

European Chemicals Agency (ECHA) (2019) 2,3-epoxypropan-1-ol; glycidol; oxiranemethanol – REACH assessment.

Deutsche Forschungsgemeinschaft (DFG) (2015) Glycidol – MAK value documentation.

International Agency for Research on Cancer (IARC) (2000) Glycidol. IARC Monographs on the evaluation of the carcinogenic risk to humans.

National Industrial Chemicals Notification and Assessment Scheme (NICNAS) (2015) Oxiranemethanol: Human health tier II assessment – IMAP report.

National Toxicology Program (NTP) (2009) NTP-RoC: Glycidol.

Tenth Adaptation to Technical Progress Commission Regulation (EU) No 2017/776 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (the CLP Regulation).

US National Institute for Occupational Safety and Health (NIOSH) (1994) Immediately dangerous to life or health concentrations – Glycidol.